Eli Lilly's Q2 adjusted EPS was $8.38, significantly exceeding the expected $6.01; revenue reached $22.97 billion, higher than the anticipated $20.73 billion. Of this, Mounjaro revenue was $9.94 billion, a year-over-year increase of 91%; Zepbound revenue was $4.93 billion, a year-over-year increase of 44%. The company raised its full-year revenue guidance from $82-85 billion to $85-87 billion, and increased its adjusted EPS guidance to $35.50-36.50.